- Home
- CANF vs SNX Comparison
CANF vs SNX Comparison
Compare CANF & SNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | SNX |
|---|---|---|
| Founded | 1994 | 1980 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 12.8B |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | CANF | SNX |
|---|---|---|
| Price | $0.28 | $154.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $6.75 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 19.7M | 604.7K |
| Earning Date | 02-03-2026 | 01-08-2026 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | N/A | ★ 18.98 |
| EPS | N/A | ★ 9.21 |
| Revenue | $560,000.00 | ★ $60,973,509,000.00 |
| Revenue This Year | $461.72 | $7.25 |
| Revenue Next Year | N/A | $4.50 |
| P/E Ratio | ★ N/A | $16.91 |
| Revenue Growth | N/A | ★ 6.94 |
| 52 Week Low | $0.28 | $92.23 |
| 52 Week High | $2.33 | $167.76 |
Technical Indicators
Market Signals| Indicator | CANF | SNX |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 55.84 |
| Support Level | $0.31 | $152.97 |
| Resistance Level | $0.33 | $158.68 |
| Average True Range (ATR) | 0.03 | 2.96 |
| MACD | 0.00 | 0.69 |
| Stochastic Oscillator | 0.71 | 75.04 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.